Top

Published in:

01-03-2014 | Original Article

shRNA-mediated silencing of ZFX attenuated the proliferation of breast cancer cells

Authors: Hongjian Yang, Yue Lu, Yabing Zheng, Xingfei Yu, Xianghou Xia, Xiangming He, Weiliang Feng, Lei Xing, Zhiqiang Ling

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2014

Abstract

Purpose

Breast cancer is the cause for highest number of cancer-related death among women worldwide. This study was focused on investigating the role of zinc-finger protein X-linked (ZFX) in human breast cancer.

Methods

Expression levels of ZFX were analyzed in 99 patients and four breast cancer cell lines. Lentivirus-mediated RNA interference was applied to silence ZFX expression, and the effects of ZFX knockdown on the growth of breast cancer cells were investigated.

Results

The immunohistochemical expression of ZFX was higher in more advanced tumor tissues. ZFX was also overexpressed in multiple breast cancer cell lines. Knockdown of ZFX inhibited cell proliferation and colony formation of MCF-7 and MDA-MB-231 cells. Moreover, ZFX silencing resulted in cell cycle arrest at G0/G1 phase. Depletion of ZFX decreased the phosphorylation level of AKT and increased the phosphorylation level of ERK2 and the expression of cyclin D1, which is involved in cell survival and cell cycle regulation.

Conclusions

These findings suggest that ZFX plays an important role in breast cancer development and could be a potential therapeutic target for breast cancer.

Siegel RN, Jemal D, Jemal A (2012) Cancer statistics, 2012. CA A Cancer J Clin 62:10–29CrossRef

Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70PubMedCrossRef

Storvold GL, Andersen TI, Perou CM, Frengen E (2006) siRNA: a potential tool for future breast cancer therapy? Crit Rev Oncog 12:127–150PubMedCrossRef

Wang YH, Liu S, Zhang G, Zhou CQ, Zhu HX, Zhou XB, Quan LP, Bai LF, Xu NZ (2005) Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Res 7:R220–R228PubMedCentralPubMedCrossRef

Wang X, Lu H, Urvalek AM, Li T, Yu L, Lamar J, DiPersio CM, Feustel PJ, Zhao J (2011) KLF8 promotes human breast cancer cell invasion and metastasis by transcriptional activation of MMP9. Oncogene 30:1901–1911PubMedCrossRef

Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494–498PubMedCrossRef

Devi GR (2006) siRNA-based approaches in cancer therapy. Cancer Gene Ther 13:819–829PubMedCrossRef

Laity JH, Lee BM, Wright PE (2001) Zinc finger proteins: new insights into structural and functional diversity. Curr Opin Struct Biol 11:39–46PubMedCrossRef

Iwase M, Satta Y, Hirai Y, Hirai H, Imai H, Takahata N (2003) The amelogenin loci span ancient pseudoautosomal boundary in diverse mammalian species. Proc Natl Acad Sci USA 100:5258–5263PubMedCrossRef

10.

Luoh SW, Bain P, Polakiewicz RD, Goodheart M, Gardner H, Jaenisch R, Page DC (1997) Zfx mutation results in small animal size and reduced germ cell number in male and female mice. Development 124:2275–2284PubMed

11.

Huang D, Gao Q, Guo L, Zhang C, Jiang W, Li H, Wang J, Han X, Shi Y, Lu SH (2009) Isolation and identification of cancer stem-like cells in esophageal carcinoma cell lines. Stem Cells Dev 18(3):465–473. doi:10.1089/scd 2008.0033PubMedCrossRef

12.

Tricoli JV, Bracken RB (1993) ZFY gene expression and retention in human prostate adenocarcinoma. Genes Chromosomes Cancer 6(2):65–72PubMedCrossRef

13.

Sakhinia E, Glennie C, Hoyland JA, Menasce LP, Brady G, Miller C, Radford JA, Byers RJ (2007) Clinical quantitation of diagnostic and predictive gene expression levels in follicular and diffuse large B-cell lymphoma by RT-PCR gene expression profiling. Blood 109(9):3922–3928. doi:10.1182/blood-2006-09-046391 PubMedCrossRef

14.

Nikpour P, Emadi-Baygi M, Mohammad-Hashem F, Maracy MR, Haghjooy-Javanmard S (2012) Differential expression of ZFX gene in gastric cancer. J Biosci 37(1):85–90PubMedCrossRef

15.

Arenzana TL, Smith-Raska MR, Reizis B (2009) Transcription factor Zfx controls BCR-induced proliferation and survival of B lymphocytes. Blood 113:5857–5867PubMedCrossRef

16.

Schnabl B, Valletta D, Kirovski G, Hellerbrand C (2011) Zinc finger protein 267 is up-regulated in hepatocellular carcinoma and promotes tumor cell proliferation and migration. Exp Mol Pathol 3:695–701CrossRef

17.

Cobaleda C, Perez-Caro M, Vicente-Duenas C, Sanchez-Garcia I (2007) Function of the zinc-finger transcription factor SNAI2 in cancer and development. Annu Rev Genet 41:41–61PubMedCrossRef

18.

Poloumienko A (2004) Cloning and comparative analysis of the bovine, porcine, and equine sex chromosome genes ZFX and ZFY. Genome 47:74–83PubMedCrossRef

19.

Schneider-Gadicke A, Beer-Romero P, Brown LG, Nussbaum R, Page DC (1989) ZFX has a gene structure similar to ZFY, the putative human sex determinant, and escapes X inactivation. Cell 57:1247–1258PubMedCrossRef

20.

Stewart SA, Dykxhoorn DM, Palliser D, Mizyno H, Yu EY, An DS, Sabatini DM, Chen ISY, Hahn WC, Sharp PA, Weinberg RA, Novina CD (2003) Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 9:493–501PubMedCrossRef

21.

Yuan J, Yan R, Krämer A, Eckerdt F, Roller M, Kaufmann M, Strebhardt K (2004) Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells. Oncogene 23:5843–5852PubMedCrossRef

22.

Kranenburg O, van der Eb AJ, Zantema A (1996) Cyclin D1 is an essential mediator of apoptotic neuronal cell death. EMBO J 15:46–54PubMed

23.

Wu S, Lao XY, Sun TT, Ren LL, Kong X, Wang JL, Wang YC, Du W, Yu YN, Weng YR, Hong J, Fang JY (2013) Knockdown of ZFX inhibits gastric cancer cell growth in vitro and in vivo via downregulating the ERK-MAPK pathway. Cancer Lett 337(2):293–300. doi:10.1016/j.canlet.2013.04.003 PubMedCrossRef

Title: shRNA-mediated silencing of ZFX attenuated the proliferation of breast cancer cells
Authors: Hongjian Yang
Yue Lu
Yabing Zheng
Xingfei Yu
Xianghou Xia
Xiangming He
Weiliang Feng
Lei Xing
Zhiqiang Ling
Publication date: 01-03-2014
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 3/2014
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-014-2379-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2014

Age affects pegylated liposomal doxorubicin elimination and tolerability in patients over 70 years old

A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors

Pharmacokinetics of liposomal-encapsulated and un-encapsulated vincristine after injection of liposomal vincristine sulfate in beagle dogs

Extraction of tamoxifen and its metabolites from formalin-fixed, paraffin-embedded tissues: an innovative quantitation method using liquid chromatography and tandem mass spectrometry

The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects

Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies

Keynote webinar | Spotlight on antibody–drug conjugates in cancer